EUVIMEDEUVIMED entdecken
Validierungsstudie

Development and Validation of a Disease‐Specific, Patient‐Reported Outcome Measure: The Myotonic Dystrophy Type 2 Health Index

Charlotte Engebrecht iD, Spencer Rosero, Jennifer Weinstein, Anika Varma, Jamison Seabury, John Heatwole, Christina Shupe, Charlotte Irwin, Preshetha Kanagaiah, Alicia Brocht, Nuran Dilek, Chad Heatwole iD

Muscle & Nerve · 2026

DOI: 10.1002/mus.70084 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Charlotte Engebrecht und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Rochester, Center for Health + Technology, Rochester, New York, USA. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Myotonic Dystrophy. Die Arbeit nennt 45 Literaturangaben. Gefördert von: NIAMS NIH HHS, Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, The Muscular Dystrophy Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims To optimize therapeutic trials involving individuals with myotonic dystrophy type 2 (DM2), it is useful to have a fully validated, regulatory‐grade, disease‐specific patient‐reported outcome (PRO) measure that is capable of detecting clinically relevant changes in response to therapeutic interventions and designed in accordance with U.S. Food and Drug Administration guidelines. The purpose of this research was to develop and validate a DM2‐specific instrument that is relevant to the patient population and capable of quantifying multifactorial disease.

Methods

We conducted semi‐structured qualitative interviews and a cross‐sectional study to identify the most important and prevalent symptoms for individuals with DM2. Symptom items were selected for inclusion in the Myotonic Dystrophy Type 2 Health Index (MD2HI) based on their high prevalence, relative impact, and potential ability to respond to therapeutic intervention. Further validation and optimization of the MD2HI were performed through beta interviews, test–retest reliability assessments, factor analysis, and subgroup analysis.

Results

Seventy‐four individuals with DM2 participated in a cross‐sectional study to identify the most common and important symptoms to include in the MD2HI. Beta testing with 20 participants with DM2 demonstrated that the MD2HI is highly relevant, easy to use, and comprehensive. During a short longitudinal study of 24 DM2 participants, the MD2HI depicted high reliability (ICC = 0.97) and high internal consistency (Cronbach's α = 0.98), resulting in a 17‐subscale instrument.

Discussion

Initial assessment of the MD2HI provides evidence that it is a valid and reliable PRO capable of quantifying a patient's perception of their disease burden to better detect clinically relevant changes in response to therapeutic intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresMyotonic DystrophyHumansMaleFemaleMiddle AgedCross-Sectional StudiesAdultReproducibility of ResultsAged

Stichwörter der Autor:innen

clinical outcome assessmentdrug labelmyotonic dystrophy type‐2neuromuscular disorderpatient‐reported outcome measure

Autor:innen und Institutionen

  • University of Rochester, Center for Health + Technology, Rochester, New York, USA.
  • University of Utah, Spencer Fox Eccles School of Medicine, Salt Lake City, Utah, USA.
  • University of Rochester, School of Medicine and Dentistry, Rochester, New York, USA.
  • Cornell University, Ithaca, New York, USA.
  • Department of Biostatistics and Neurology, University of Rochester, Rochester, New York, USA.
  • Department of Neurology, University of Rochester, Rochester, New York, USA.

ORCID-Profile: Charlotte Engebrecht, Chad Heatwole

Förderung

  • NIAMS NIH HHS
  • Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center
  • The Muscular Dystrophy Association
  • The New York State Empire Clinical Research Investigator Program
  • The Goldberg Nathan Myotonic Dystrophy Type-2 Fund
  • The Gilbert Gottfried Myotonic Dystrophy Type 2 Research Fund
  • University of Rochester
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Engebrecht, C., Rosero, S., Weinstein, J., Varma, A., Seabury, J., Heatwole, J., Shupe, C., Irwin, C., Kanagaiah, P., Brocht, A., Dilek, N., & Heatwole, C. (2026). Development and Validation of a Disease‐Specific, Patient‐Reported Outcome Measure: The Myotonic Dystrophy Type 2 Health Index. Muscle & Nerve. https://doi.org/10.1002/mus.70084

Vancouver

Engebrecht C, Rosero S, Weinstein J, Varma A, Seabury J, Heatwole J, et al. Development and Validation of a Disease‐Specific, Patient‐Reported Outcome Measure: The Myotonic Dystrophy Type 2 Health Index. Muscle & Nerve. 2026. doi:10.1002/mus.70084

BibTeX
@article{Engebrecht2026,
  author = {Engebrecht, Charlotte and Rosero, Spencer and Weinstein, Jennifer and Varma, Anika and Seabury, Jamison and Heatwole, John and Shupe, Christina and Irwin, Charlotte and Kanagaiah, Preshetha and Brocht, Alicia and Dilek, Nuran and Heatwole, Chad},
  title = {Development and Validation of a Disease‐Specific, Patient‐Reported Outcome Measure: The Myotonic Dystrophy Type 2 Health Index},
  journal = {Muscle & Nerve},
  year = {2026},
  doi = {10.1002/mus.70084}
}
Kostenlos starten →